LAUSR

Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), also called COVID-19 disease, was firstly reported in December 2019 in China and soon declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In Italy, on June 14, 2020, we report 236,989 infected patients and 34,345 deaths. Although Campania Region is among the less affected regions, 4609 SARS-Cov-2 cases have occurred. 2019-nCoV, a single-strand RNA virus responsible for COVID-19, spreads by human-to-human transmission. Most common transmission vehicles are respiratory droplets, aerosols and conjunctiva, but the virus can also persist on surfaces. COVID-19 may be asymptomatic till severe illness, i.e., severe pneumonia and death [1, 2]. Due to the rapid outbreak of COVID-19, concern has been growing about the management of rheumatic patients, particularly due to risk of infection and immunosuppressive treatments. Rheumatic patients taking immunomodulators may be more susceptible to the infection, mainly in combination with biologic drugs [3]. Unlike other viruses (e.g., influenza), coronaviruses have not been shown to evolve to the more severe stages of the disease in immunosuppressed patients [4]. Usually, discontinuing therapeutic treatment is not recommended, since clinical flares of rheumatic disease develop with subsequent use of other immunosuppressants such as corticosteroids, equally unsafe in the case of COVID-19 occurrence [3]. Indeed, the risk of infection in rheumatic patients (i.e., rheumatoid arthritis) is also related to disease activity and a flare due to therapy interruption would confer an increased risk of infection. The European League Against Rheumatism (EULAR) and the Italian Society of Rheumatology (SIR) clinical guidance during COVID-19 pandemic recommended management of patients on long-term corticosteroid therapy by gradually tapering doses, and warning against abrupt cessation of corticosteroid therapy, even during active infection. Discontinuation of disease-modifying antirheumatic drugs, biologics, small molecules, and other immunosuppressive agents has been suggested just in case of overt infection [5]. SIR has also promoted a dedicated platform, “CONTROL-19”, for the remote monitoring of COVID-19 impact on rheumatic diseases [6]. In our internal medicine outpatient, we have closely monitored patients with severe active disease either via phone-calls or e-mail, rescheduling the great majority of appointments and implementing restrictive measures at a social level [7]. We have selected patients that could not postpone their infusion, providing them with specific recommendations. In cases of extremely urgent need to initiate treatment, subcutaneous infusions were preferred over intravenous biologics, as they can be taken at home. An objective phone interview has been carried out before admission to assess for acute respiratory symptoms, and/or fever, and exclude contact with positive COVID-19 patients during the past 14 days. Infusions have been provided in a dedicated Rheumatology INTERNATIONAL